Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tecnimede - Sociedade Técnico-Medicinal SA currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, requiring the company to manage separate examiner relationships simultaneously. The portfolio is also active across 2 distinct art units, indicating that the company's pharmaceutical research is being evaluated by different specialized groups within the patent office. This distribution suggests a varied approach to the company's biotechnology and pharmaceutical filings.
Po-Chih Chen is the busiest examiner for the company, currently overseeing 1 pending office action. This represents 1 of the 2 pending office actions for the portfolio, as the workload is distributed among the 2 distinct examiners. Practitioners should be prepared to tailor their arguments to the specific requirements of each art unit involved in the Biotechnology & Pharmaceuticals sector to resolve these outstanding matters. Managing these examiner interactions effectively will be key to advancing the company's current patent applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| NGUYEN, NGOC-ANH THI | 1 | 28.1% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575643 | Heterocyclic compounds for the treatment of tuberculosis | CHEN, PO-CHIH | 4d overdue |
| 17622305 | COMPRESSED MACITENTAN COMPOSITIONS, METHODS AND USES THEREOF | NGUYEN, NGOC-ANH THI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575643 | Heterocyclic compounds for the treatment of tuberculosis | CHEN, PO-CHIH | 4d overdue |
| 17622305 | COMPRESSED MACITENTAN COMPOSITIONS, METHODS AND USES THEREOF | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575643 | Heterocyclic compounds for the treatment of tuberculosis | CHEN, PO-CHIH | 1621 | §103§112 | Non-Final OA | 4d overdue | Pending | Dec 29, 2023 |
| 17622305 | COMPRESSED MACITENTAN COMPOSITIONS, METHODS AND USES THEREOF | NGUYEN, NGOC-ANH THI | 1615 | §102 | Final Rejection | — | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial